Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial
复制标题
DOI：
10.4088/jcp.21m14130
复制
发表时间：
2022-09-01
影响因子：
5.3
通讯作者：
Amminger, G. Paul
中科院分区：
文献类型：
--
作者：
Berger, Maximus;Li, Emily;Amminger, G. Paul
背景：在经历中度至重度焦虑的年轻人中，治疗耐药性是一个重要问题，影响了近一半的患者。这项研究调查了大麻二酚（CBD）的安全性和有效性，大麻二酚是大麻的一种非中毒成分，用于治疗以前对标准治疗无效的年轻人的焦虑症。方法：在这项开放标签试验中，在2018年5月16日至2019年6月28日期间，招募了31名年龄在12-25岁的患有DSM-5焦虑症的年轻人，尽管接受了认知行为疗法和/或抗抑郁药物治疗，但没有临床改善。所有参与者都接受了为期12周的CBD附加治疗，按固定灵活的时间表滴定至800毫克/天。主要结局是焦虑严重程度的改善，在第12周用总体焦虑严重程度和损害量表（OASIS）测量。次要结局包括共病抑郁症状、临床总体印象量表（CGI）评分、社会和职业功能。结果：平均（SD） OASIS评分从基线时的10.8分（3.8分）下降到第12周时的6.3分（4.5分），对应于-42.6%的下降(P
Background: Treatment resistance is a significant problem among young people experiencing moderate-to-severe anxiety, affecting nearly half of all patients. This study investigated the safety and efficacy of cannabidiol (CBD), a non-intoxicating component of Cannabis sativa, for anxiety disorders in young people who previously failed to respond to standard treatment. Methods: In this open-label trial, 31 young people aged 12-25 years with a DSM-5 anxiety disorder and no clinical improvement despite treatment with cognitive-behavioral therapy and/or antidepressant medication were enrolled between May 16, 2018, and June 28, 2019. All participants received add-on CBD for 12 weeks on a fixed-flexible schedule titrated up to 800 mg/d. The primary outcome was improvement in anxiety severity, measured with the Overall Anxiety Severity and Impairment Scale (OASIS), at week 12. Secondary outcomes included comorbid depressive symptoms, Clinical Global Impressions scale (CGI) score, and social and occupational functioning. Results: Mean (SD) OASIS scores decreased from 10.8 (3.8) at baseline to 6.3 (4.5) at week 12, corresponding to a -42.6% reduction (P